2019
DOI: 10.1111/bjd.17696
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Summary Background Atopic eczema is an inflammatory skin condition, with a similar impact on health‐related quality of life as other chronic diseases. Increasing pressures on resources within the National Health Service increase the importance of having good economic evidence to inform their allocation. Objectives To educate dermatologists about economic methods with reference to currently available economic evidence on eczema. Methods The role of different types of economic evidence is illustrated by evidence… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
13
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 11 publications
(13 citation statements)
references
References 104 publications
0
13
0
Order By: Relevance
“…Most of the studies included were conducted for the US or a European country—particularly the UK, Italy, or Germany. Other reviews have also found that most studies are conducted for the US and Europe—and that the UK, Italy, and Germany are several European countries that are often included [ 25 , 26 , 28 , 38 , 41 ]. However, other reviews have normally found a higher proportion of studies to have been conducted in Europe, suggesting that economic evaluations and cost studies of immunological skin conditions may be more commonly conducted for the US compared to other conditions.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Most of the studies included were conducted for the US or a European country—particularly the UK, Italy, or Germany. Other reviews have also found that most studies are conducted for the US and Europe—and that the UK, Italy, and Germany are several European countries that are often included [ 25 , 26 , 28 , 38 , 41 ]. However, other reviews have normally found a higher proportion of studies to have been conducted in Europe, suggesting that economic evaluations and cost studies of immunological skin conditions may be more commonly conducted for the US compared to other conditions.…”
Section: Discussionmentioning
confidence: 99%
“…Those studies have shown that many economic evaluations have been conducted for the US and European region, and many have been conducted from the perspective of the payer—i.e., from the perspective of the national health insurance system or another third-party insurer. While the quality of the economic evaluation studies conducted has been reported to be high, a lack of reporting of study characteristics and variability in methods used across studies despite similar therapy areas have been suggested [ 25 , 27 , 28 ]. For example, studies have failed to report the study perspective (e.g., payer perspective, societal perspective), which is an important consideration when determining the types of costs to include in the analysis.…”
Section: Introductionmentioning
confidence: 99%
“…Neither of these studies included a control cohort, and they were limited by sample sizes (range 33–474) and follow-up duration (range 3 months–8 years). In another systematic review of economic evidence for prevention and treatment of atopic eczema, four additional European studies were identified, but none included stratification by severity [ 21 ].…”
Section: Introductionmentioning
confidence: 99%
“…In the era of finite resources in a highly demanded healthcare system, health economics has become increasingly influential in the optimization of healthcare expenditure . Cost‐of‐illness studies summarize the financial burden of an illness on a given population . Without effectiveness evidence, data from such studies cannot sufficiently inform resource allocation.…”
mentioning
confidence: 99%
“…To date, many studies have emerged evaluating the economic burden of AD . However, due to heterogeneous study objectives, methodologies and settings, their implications are limited to certain populations and healthcare systems. More comprehensive and up‐to‐date studies on the economic burden of AD are therefore needed, particularly in the U.K., where the last relevant study on the cost of AD was published in 1996 …”
mentioning
confidence: 99%